Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients : an updated network meta-analysis of randomized placebo-controlled trials
BACKGROUND: Many recent studies have investigated the role of drug interventions for coronavirus disease 2019 (COVID-19) infection. However, an important question has been raised about how to select the effective and secure medications for COVID-19 patients. The aim of this analysis was to assess the efficacy and safety of the various medications available for severe and non-severe COVID-19 patients based on randomized placebo-controlled trials (RPCTs).
METHODS: We did an updated network meta-analysis. We searched the databases from inception until July 31, 2021, with no language restrictions. We included RPCTs comparing 49 medications and placebo in the treatment of severe and non-severe patients (aged 18 years or older) with COVID-19 infection. We extracted data on the trial and patient characteristics, and the following primary outcomes: all-cause mortality, the ratios of virological cure, and treatment-emergent adverse events. Odds ratio (OR) and their 95% confidence interval (CI) were used as effect estimates.
RESULTS: From 3,869 publications, we included 61 articles related to 73 RPCTs (57 in non-severe COVID-19 patients and 16 in severe COVID-19 patients), comprising 20,680 patients. The mean sample size was 160 (interquartile range 96-393) in this study. The median duration of follow-up drugs intervention was 28 days (interquartile range 21-30). For increase in virological cure, we only found that proxalutamide (OR 9.16, 95% CI 3.15-18.30), ivermectin (OR 6.33, 95% CI 1.22-32.86), and low dosage bamlanivimab (OR 5.29, 95% CI 1.12-24.99) seemed to be associated with non-severe COVID-19 patients when compared with placebo, in which proxalutamide seemed to be better than low dosage bamlanivimab (OR 5.69, 95% CI 2.43-17.65). For decrease in all-cause mortality, we found that proxalutamide (OR 0.13, 95% CI 0.09-0.19), imatinib (OR 0.49, 95% CI 0.25-0.96), and baricitinib (OR 0.58, 95% CI 0.42-0.82) seemed to be associated with non-severe COVID-19 patients; however, we only found that immunoglobulin gamma (OR 0.27, 95% CI 0.08-0.89) was related to severe COVID-19 patients when compared with placebo. For change in treatment-emergent adverse events, we only found that sotrovimab (OR 0.21, 95% CI 0.13-0.34) was associated with non-severe COVID-19 patients; however, we did not find any medications that presented a statistical difference when compared with placebo among severe COVID-19 patients.
CONCLUSION: We conclude that marked variations exist in the efficacy and safety of medications between severe and non-severe patients with COVID-19. It seems that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. Clinical decisions to use preferentially medications should carefully consider the risk-benefit profile based on efficacy and safety of all active interventions in patients with COVID-19 at different levels of infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Aging - 13(2021), 18 vom: 16. Sept., Seite 21866-21902 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cheng, Qinglin [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 15.10.2021 Date Revised 03.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.18632/aging.203522 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330733036 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM330733036 | ||
003 | DE-627 | ||
005 | 20231225211922.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.18632/aging.203522 |2 doi | |
028 | 5 | 2 | |a pubmed24n1102.xml |
035 | |a (DE-627)NLM330733036 | ||
035 | |a (NLM)34531332 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cheng, Qinglin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients |b an updated network meta-analysis of randomized placebo-controlled trials |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.10.2021 | ||
500 | |a Date Revised 03.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Many recent studies have investigated the role of drug interventions for coronavirus disease 2019 (COVID-19) infection. However, an important question has been raised about how to select the effective and secure medications for COVID-19 patients. The aim of this analysis was to assess the efficacy and safety of the various medications available for severe and non-severe COVID-19 patients based on randomized placebo-controlled trials (RPCTs) | ||
520 | |a METHODS: We did an updated network meta-analysis. We searched the databases from inception until July 31, 2021, with no language restrictions. We included RPCTs comparing 49 medications and placebo in the treatment of severe and non-severe patients (aged 18 years or older) with COVID-19 infection. We extracted data on the trial and patient characteristics, and the following primary outcomes: all-cause mortality, the ratios of virological cure, and treatment-emergent adverse events. Odds ratio (OR) and their 95% confidence interval (CI) were used as effect estimates | ||
520 | |a RESULTS: From 3,869 publications, we included 61 articles related to 73 RPCTs (57 in non-severe COVID-19 patients and 16 in severe COVID-19 patients), comprising 20,680 patients. The mean sample size was 160 (interquartile range 96-393) in this study. The median duration of follow-up drugs intervention was 28 days (interquartile range 21-30). For increase in virological cure, we only found that proxalutamide (OR 9.16, 95% CI 3.15-18.30), ivermectin (OR 6.33, 95% CI 1.22-32.86), and low dosage bamlanivimab (OR 5.29, 95% CI 1.12-24.99) seemed to be associated with non-severe COVID-19 patients when compared with placebo, in which proxalutamide seemed to be better than low dosage bamlanivimab (OR 5.69, 95% CI 2.43-17.65). For decrease in all-cause mortality, we found that proxalutamide (OR 0.13, 95% CI 0.09-0.19), imatinib (OR 0.49, 95% CI 0.25-0.96), and baricitinib (OR 0.58, 95% CI 0.42-0.82) seemed to be associated with non-severe COVID-19 patients; however, we only found that immunoglobulin gamma (OR 0.27, 95% CI 0.08-0.89) was related to severe COVID-19 patients when compared with placebo. For change in treatment-emergent adverse events, we only found that sotrovimab (OR 0.21, 95% CI 0.13-0.34) was associated with non-severe COVID-19 patients; however, we did not find any medications that presented a statistical difference when compared with placebo among severe COVID-19 patients | ||
520 | |a CONCLUSION: We conclude that marked variations exist in the efficacy and safety of medications between severe and non-severe patients with COVID-19. It seems that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. Clinical decisions to use preferentially medications should carefully consider the risk-benefit profile based on efficacy and safety of all active interventions in patients with COVID-19 at different levels of infection | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a efficacy | |
650 | 4 | |a network meta-analysis | |
650 | 4 | |a randomized placebo-controlled trials | |
650 | 4 | |a safety | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Azetidines |2 NLM | |
650 | 7 | |a Immunologic Factors |2 NLM | |
650 | 7 | |a Oxazoles |2 NLM | |
650 | 7 | |a Purines |2 NLM | |
650 | 7 | |a Pyrazoles |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a Thiohydantoins |2 NLM | |
650 | 7 | |a sotrovimab |2 NLM | |
650 | 7 | |a 1MTK0BPN8V |2 NLM | |
650 | 7 | |a bamlanivimab |2 NLM | |
650 | 7 | |a 45I6OFJ8QH |2 NLM | |
650 | 7 | |a Imatinib Mesylate |2 NLM | |
650 | 7 | |a 8A1O1M485B |2 NLM | |
650 | 7 | |a baricitinib |2 NLM | |
650 | 7 | |a ISP4442I3Y |2 NLM | |
650 | 7 | |a proxalutamide |2 NLM | |
650 | 7 | |a QX6O64GP40 |2 NLM | |
700 | 1 | |a Chen, Junfang |e verfasserin |4 aut | |
700 | 1 | |a Jia, Qingjun |e verfasserin |4 aut | |
700 | 1 | |a Fang, Zijian |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Gang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Aging |d 2008 |g 13(2021), 18 vom: 16. Sept., Seite 21866-21902 |w (DE-627)NLM192249398 |x 1945-4589 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2021 |g number:18 |g day:16 |g month:09 |g pages:21866-21902 |
856 | 4 | 0 | |u http://dx.doi.org/10.18632/aging.203522 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2021 |e 18 |b 16 |c 09 |h 21866-21902 |